Understanding how certain proteins affect cancer growth and treatment resistance in colorectal cancer
Official title: Regulation of RBP Function during EMT
Funded at University of Nebraska Medical Center · NIH-11081804 · Data updated 2026-11-12
This study is looking at how certain proteins affect colorectal cancer, especially how they help cancer cells grow and become tougher against treatments, with the hope of finding better ways to target and treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $420,208 |
| NIH project number | 5R01CA277495-02 |
| Project ID | NIH-11081804 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with colorectal cancer, particularly those with KRAS mutations.
✕Less likely to help
Patients with non-colorectal cancers or those without KRAS mutations may not benefit from this research.
What this research studies
This research investigates the role of specific proteins in colorectal cancer, particularly focusing on how they influence tumor initiation and the transition of cancer cells to a more aggressive state. By studying tumor initiating cells (TICs), which are known to contribute to drug resistance, the research aims to uncover the mechanisms that allow these cells to survive and proliferate. The team will utilize advanced techniques to analyze gene interactions and protein functions, which could lead to new insights into how to effectively target and treat colorectal cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for colorectal cancer by targeting the mechanisms that drive tumor growth and resistance.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Lewis, Robert E. — University of Nebraska Medical Center
- Study coordinator: Lewis, Robert E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.